Evaluation of in situ albumin binding surfaces: a study of protein adsorption and platelet adhesion

2010 ◽  
Vol 22 (1) ◽  
pp. 137-149 ◽  
Author(s):  
Sanjukta Guha Thakurta ◽  
Anuradha Subramanian
2015 ◽  
Vol 3 (9) ◽  
pp. 1921-1930 ◽  
Author(s):  
Xiajun Zheng ◽  
Chong Zhang ◽  
Longchao Bai ◽  
Songtao Liu ◽  
Lin Tan ◽  
...  

A series of well-controlled bottle-brush poly(methylacrylic acid)-graft-poly(2-methyl-2-oxazoline) copolymers were grafted to gold surfaces through an in situ aminolysis reaction to reduce protein adsorption and platelet adhesion.


2012 ◽  
Vol 7 (4) ◽  
pp. 045007 ◽  
Author(s):  
Sanjukta Guha Thakurta ◽  
Robert Miller ◽  
Anuradha Subramanian

2020 ◽  
Vol 40 (04) ◽  
pp. 524-535
Author(s):  
Dmitry Y. Nechipurenko ◽  
Aleksey M. Shibeko ◽  
Anastasia N. Sveshnikova ◽  
Mikhail A. Panteleev

AbstractComputational physiology, i.e., reproduction of physiological (and, by extension, pathophysiological) processes in silico, could be considered one of the major goals in computational biology. One might use computers to simulate molecular interactions, enzyme kinetics, gene expression, or whole networks of biochemical reactions, but it is (patho)physiological meaning that is usually the meaningful goal of the research even when a single enzyme is its subject. Although exponential rise in the use of computational and mathematical models in the field of hemostasis and thrombosis began in the 1980s (first for blood coagulation, then for platelet adhesion, and finally for platelet signal transduction), the majority of their successful applications are still focused on simulating the elements of the hemostatic system rather than the total (patho)physiological response in situ. Here we discuss the state of the art, the state of the progress toward the efficient “virtual thrombus formation,” and what one can already get from the existing models.


2016 ◽  
Vol 24 (5) ◽  
pp. 4812 ◽  
Author(s):  
Judit Nador ◽  
Benjamin Kalas ◽  
Andras Saftics ◽  
Emil Agocs ◽  
Peter Kozma ◽  
...  

2010 ◽  
Vol 81 (1) ◽  
pp. 58-66 ◽  
Author(s):  
M.A. McArthur ◽  
T.M. Byrne ◽  
R.J. Sanderson ◽  
G.P. Rockwell ◽  
L.B. Lohstreter ◽  
...  

2021 ◽  
Vol 12 (10) ◽  
pp. 1589-1595
Author(s):  
Lixue Chen ◽  
Shengnan Li ◽  
Yanfang Ding ◽  
Changyuan Wang ◽  
Sitong Zhang ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 14 (1) ◽  
pp. 83
Author(s):  
Hanhee Cho ◽  
Man Kyu Shim ◽  
Suah Yang ◽  
Sukyung Song ◽  
Yujeong Moon ◽  
...  

Prodrugs are bioreversible medications that should undergo an enzymatic or chemical transformation in the tumor microenvironment to release active drugs, which improve cancer selectivity to reduce toxicities of anticancer drugs. However, such approaches have been challenged by poor therapeutic efficacy attributed to a short half-life and low tumor targeting. Herein, we propose cathepsin B-overexpressed tumor cell activatable albumin-binding doxorubicin prodrug, Al-ProD, that consists of a albumin-binding maleimide group, cathepsin B-cleavable peptide (FRRG), and doxorubicin. The Al-ProD binds to in situ albumin, and albumin-bound Al-ProD indicates high tumor accumulation with prolonged half-life, and selctively releases doxorubicin in cathepsin B-overexpressed tumor cells, inducing a potent antitumor efficacy. Concurrently, toxicity of Al-ProD toward normal tissues with innately low cathepsin B expression is significantly reduced by maintaining an inactive state, thereby increasing the safety of chemotherapy. This study offers a promising approach for effective and safe chemotherapy, which may open new avenues for drug design and translational medicine.


Sign in / Sign up

Export Citation Format

Share Document